I deeply appreciate this important topic brought to us by Dr. Michelle Barrow as she answers questions put to her by our Nutrition Programs Director, Romilly Hodges. This exchange was prompted by Dr. Barrow’s recent peer-reviewed publication – Transforming Personalized Nutrition Practice – a worthwhile read which came across Romilly’s desk earlier this year. After all, personalized nutrition is a core component of the Functional Medicine toolkit. As a profession (of both functional medicine and personalized nutrition practitioners), we need take steps to bridge the gap between currently-accepted evidence models and what is actually needed to support our practice. We need to ask the hard questions; and take the steps to build a better model. It’s something I have proposed before, and I am absolutely delighted to continue to champion. – DrKF
Uterine fibroids are a huge, underappreciated issue. They are the most common gynecological disorder, affecting nearly half of women younger than 40 years old, and far more (~80%) for those older. Frankly, I don’t think we are doing enough to help these patients. Fibroids are the leading indication for hysterectomy in the US, accounting for 39% of all hysterectomies each year, and while some are asymptomatic, symptoms include heavy and prolonged periods, difficulty with intercourse, bowel dysfunction, non-cyclic pelvic pain, low back pain, urinary frequency and urgency, and constipation. Because not all fibroids cause heavy bleeding, their impact can be missed, think: refractory constipation or incontinence. Conventional treatments include pharmacotherapy, surgical interventions, and uterine artery embolization, however, these treatments leave much to be desired. Oral contraceptives are used to manage bleeding, and even after myomectomy, fibroids often recur and 10% of women will undergo hysterectomy within 5 – 10 years.
It goes without saying, although I’ll still say it again, that 2020 has been a year for the books not only in the world of Functional and Integrative medicine, but in all ways possible.
Everyone’s awareness about comorbidities, especially overweight and obesity, is heightened due to COVID-19. And in two recent WebMD polls, up to 47% of women and 55% of men report gaining weight during the lockdown – no surprise there – but this may imply patients may be more interested in achieving weight loss goals as part of their overall health care than in previous times. Except we know conventional weight loss programs that lead to a calorie deficit are woefully inadequate (even counterproductive), leading to poor resistance to infection and malnutrition, as Corey Schuler from Integrative Therapeutics explains in this blog below. Read on to learn about the immunometabolic changes brought about in obesity, how to counter them, and I for one, am super grateful Corey relays this encouraging fact: losing just 5% of body mass leads to significant benefits.
Obstructive Sleep Apnea: Using Orofacial Myofunctional Therapy as a Part of a FxMed Approach to Treatment
Obstructive Sleep Apnea is a condition affecting up to 22 million Americans and close to 1 billion people worldwide.
This condition can have serious impacts on overall health and has been shown to be a contributing factor to:
and chronic headaches
There are a variety of treatment options available to manage Obstructive Sleep Apnea including Positive Airway Pressure devices (the most common being CPAP), dental mandibular advancement appliances, and various surgeries, but there are also functional treatment approaches that can target the underlying causes of the disease.
Respiratory conditions, both chronic and acute, are some of the most common issues seen in clinical practice. In 2016, chronic obstructive pulmonary disease (COPD) alone accounted for around 3 million deaths, and was the third leading cause of death worldwide. Asthma is one of the most common chronic diseases globally affecting nearly eight percent of people (over 24 million) in the US alone. Childhood onset of asthma can impair airway development, and persist into adulthood. Adult asthma may accelerate the decline of pulmonary function, and increase susceptibility to infection
As you know, here at drkarafitzgerald.com we like to push the boundaries of what we know, and sometimes this means being a little contrarian. In this blog, our Nutrition Director, Romilly Hodges CNS takes us on a tour of some of the emerging research on Th17 prompted by a new paper in the journal Cell, that postulated a reduction in Bifidobacteria may mediate some of the benefits of a ketogenic diet for epilepsy by reducing Th17.
My first EOE patient in the early 2000’s was fortunately, already diagnosed by a very savvy Yale gastroenterologist. I hadn’t heard of EOE at that time, but quickly learned about this highly challenging and potentially disabling mixed IgE allergic condition. It was clear immediately that functional medicine was the solution, and despite my lack of awareness of EOE, I had much to offer my first patient. Since then, we’ve seen more and more EOE patients in clinical practice, unfortunately, due to the meteoric rise of this condition. Fortunately, our tools continue to benefit.
I am so grateful for the participation of the panel in the roundtable discussion on Bridging the Gaps in Functional Medicine, COVID-19 & Racial Disparities.
As research on gut barrier function and gut microbes (aka the gut “microbiota”) expands, more is realized about the interconnectedness of the human body. One of the surprising areas is in the way that an unhealthy microbiota is a key driver of obesity, fatty liver disease, metabolic syndrome, type 2 diabetes, and cardiac risk.